Filters: author is Gubbens-Stibbe [Clear All Filters]
- 2003
Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations,
J Pharmacol Exp Ther, vol. 304, no. 1, pp. 88-101. DOI
- 2002
A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia,
J Pharmacol Exp Ther, vol. 300, no. 1, pp. 330-8.
- 2000
- 1999
The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model,
Anesthesiology, vol. 90, no. 2, pp. 535-44.
- 1998
Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 159-68.
- 1997
Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease,
J Chromatogr B Biomed Sci Appl, vol. 702, no. 1-2, pp. 131-41.
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo,
J Pharmacol Exp Ther, vol. 283, no. 2, pp. 800-8.
Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease,
Pharm Res, vol. 14, no. 12, pp. 1804-10.
- 1995
Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine,
J Pharmacol Exp Ther, vol. 275, no. 1, pp. 245-53.
- 1991
Stability and pharmacokinetics of flumazenil in the rat,
Psychopharmacology (Berl), vol. 103, no. 3, pp. 384-7.


